Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
In an interview with CancerNetwork®, Yael Cohen, MD, a senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, discussed the safety profile of ciltacabtagene autoleucel in a population of patients with lenalidomide (Revlimid)–refractory multiple myeloma.
She highlighted that the safety of the CAR T-cell therapy was encouraging, with no new safety findings reading out in the phase 2 CARTITUDE-2 trial (NCT04133636).
The safety was certainly manageable. There were no new adverse effects that came out. Specifically, in the earlier parts of the development, there were some concerns about the movement and neurocognitive changes and there was a mitigation program that was put in place. Since then, the rate, when tested, went down. In this study, in particular, there were no cases. Over 200 patients were dosed in the overall program and the rate went down to 0.5%. That [was] also encouraging.
Cohen YC, Cohen AD, Delforge M, et al. Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2. Presented at: 2021 ASH Annual Meeting; December 11-13, 2021; Atlanta, GA. Poster 3866.